Substance / Medication

Romidepsin

Overview

Active Ingredient
romidepsin
RxNorm CUI
877510

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis.
Du Jun, Han Xinle, Lin Suwen et al. · Front Med (Lausanne) · 2021
PMID: 34805202Meta-AnalysisFull text (PMC)
Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas.
Ford Josie G, Koh Min Jung, Lenart Alexandra W et al. · Blood Adv · 2025
PMID: 40526834ObservationalFull text (PMC)
Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony Shai, Horowitz Netanel, Ribakovsky Elena et al. · Hematol Oncol · 2019
PMID: 31674027Observational
Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.
Zinzani Pier Luigi, Pellegrini Cinzia, Cerciello Giuseppe et al. · Leuk Lymphoma · 2016
PMID: 26732313Observational
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.
Newbold Andrea, Lindemann Ralph K, Cluse Leonie A et al. · Mol Cancer Ther · 2008
PMID: 18483296Observational
Treatment of Sezary syndrome with combination romidepsin and tofacitinib: A case report.
Suhl Sara, Lapolla Brigit, Kaminsky Alexander et al. · JAAD Case Rep · 2025
PMID: 39802947Case ReportFull text (PMC)
Improving gastrointestinal quality of life: romidepsin to tucidinostat in a case of angioimmunoblastic T cell lymphoma.
Isoda Atsushi, Terasaki Yukie, Kanaya Shuhei et al. · BMJ Case Rep · 2024
PMID: 38199657Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Romidepsin (substance)
SNOMED CT
444608004
UMLS CUI
C1527027
RxNorm CUI
877510

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.